Fasting Insulin as an Independent Predictor of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Severity

被引：0
|
作者：
Harrison, Stephen A.
Dubourg, Julie
Jeannin, Sophie
Colca, Jerry R.
Ratziu, Vlad
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-1582-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1582-P
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Noninvasive testing in the diagnosis of metabolic dysfunction-associated steatohepatitis
    Marks, Lucas M.
    Jensen, Thomas
    DeGrado, Timothy R.
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (03):
  • [42] Identification of biomarkers for the diagnosis in colorectal polyps and metabolic dysfunction-associated steatohepatitis (MASH) by bioinformatics analysis and machine learning
    Geng, Ying
    Li, Yifang
    Liu, Ge
    Jiao, Jian
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [43] New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024
    Wong, Shu Wei
    Yang, Yong-yu
    Chen, Hui
    Xie, Li
    Shen, Xi-zhong
    Zhang, Ning-ping
    Wu, Jian
    ACTA PHARMACOLOGICA SINICA, 2025,
  • [44] Non-invasive assessment of liver inflammation in metabolic dysfunction-associated steatohepatitis (MASH) using MRI cytometry
    Jiang, Xiaoyu
    Izzy, Manhal
    Washington, Kay
    Gore, John
    Xu, Junzhong
    JOURNAL OF HEPATOLOGY, 2024, 80 : S595 - S595
  • [45] METABOLISM AND THERAPEUTIC EFFECTS OF N-ACYL AMINO ACIDS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND ATHEROSCLEROSIS
    Anand, Sumit Kumar
    Das, Sandeep
    Lee, Jennifer
    Richard, Koral
    McKinney, Peyton
    Rohilla, Sumati
    Pandey, Nilesh
    Kumar, Dhananjay
    Pearson-Gallion, Brenna
    Wang, Lu
    Finney, Alexandra
    Zhang, Jifeng
    Sun, Duxin
    Liu, Wanqing
    Chen, Eugene
    Orr, Wayne
    Dhanesha, Nirav
    Yurdagul, Arif
    Rom, Oren
    HEPATOLOGY, 2024, 80
  • [46] DEGREE OF METABOLIC DYSFUNCTION IS LINKED TO STEATOHEPATITIS (MASH), FIBROSIS, AND HIGHER CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Kim, David
    Abboud, Yazan
    Ismail, Mohamed
    Goyal, Ritik Mahaveer
    Pyrsopoulos, Nikolaos
    Kim, Hyunseok
    Hajifathalian, Kaveh
    Al-Khazraji, Ahmed
    HEPATOLOGY, 2024, 80 : S441 - S442
  • [47] Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis
    Tincopa, Monica A.
    Loomba, Rohit
    SEMINARS IN LIVER DISEASE, 2024, 44 (03) : 287 - 299
  • [48] Development and validation of CLDQ-MASH: a disease specific health related quality of life instrument for patients with metabolic dysfunction-associated steatohepatitis (MASH)
    Younossi, Zobair
    Stepanova, Maria
    Younossi, Issah
    Racila, Andrei
    JOURNAL OF HEPATOLOGY, 2024, 80 : S101 - S102
  • [49] IMPROVED DIAGNOSTIC ACCURACY OF VIBRATION-CONTROLLED TRANSIENT ELASTOGRAPHY BASED TESTS IN IDENTIFYING METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND AT-RISK MASH IN OBESE AND LEAN INDIVIDUALS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Quek, Joo Wei Ethan
    Tan, En Ying
    Lee, Shi Yan
    Huang, Daniel
    Lee, Jonathan
    Teng, Margaret
    Ng, Cheng Han
    Syn, Nicholas
    Wee, Aileen
    Soon, Shook Ting Gwyneth
    Jumat, Nur Halisah
    Dan, Yock Young
    Muthiah, Mark
    HEPATOLOGY, 2024, 80 : S620 - S621
  • [50] Associations Between Laboratory Results and Mortality in Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Diabetes and Antihypertensive Drug Status
    Guillot, Jordan
    Williams, Christopher
    Slatter, Shadera
    Lo Re, Vin
    Rentsch, Christopher T.
    Ge, Jin
    Rudrapatna, Vivek
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 558 - 558
12345